Thursday, 18 July 2013

CDER Small Business Chronicles – USP Salt Policy

The Small Biz Buzz
The Information Source for Regulated Domestic and International Small Pharmaceutical Business

FDA/CDER's Small Business Assistance


 

FDA/CDER Small Business Chronicles – USP Salt Policy 

The topic of this month’s issue of the FDA/CDER Small Business Chronicles is CDER’s Application of the United States Pharmacopeia (USP) Salt Policy. The USP Salt Policy is a naming and labeling policy applicable to drug products that contain an active ingredient that is a salt. In this issue, we discuss the USP Salt Policy, how CDER is applying the Policy, exceptions to the Policy, and how it will benefit public health.

 

The purpose of the newsletter, the FDA/CDER Small Business Chronicles, is to provide industry with useful information to assist in all aspects of drug marketing and regulation.  

                   

As always, we would appreciate your input regarding topics that you would like us to write about. If you have topics of interest, please email us at CDERSmallBusiness@fda.hhs.gov

 

Our previous newsletters are also archived on our webpage at: http://www.fda.gov/cdersmallbusinesschronicles.

  

Enjoy!

 

The CDER Small Business Assistance Team 


The Small Business Assistance (SBA) program in the Center for Drug Evaluation and Research (CDER) provides guidance and information to regulated domestic and international small pharmaceutical business through its website, email notifications, and workshops. This notification system provides current information from CDER/FDA via e-mail on a biweekly basis that is relevant to small pharmaceutical business, which includes Federal Register notices, guidances, workshop announcements, etc. This is an automated message delivery system. Replying to this message will not reach the SBA staff.  If you have comments or questions, please contact us Monday through Friday 8:00AM – 4:30PM.

Please take our CDER Small Business survey: https://www.surveymonkey.com/s/cdersmallbusiness


This email was sent to buzzhairs.health@blogger.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 Powered by GovDelivery

No comments:

Post a Comment